December 20, 2017 / 12:50 PM / a month ago

BRIEF-MabVax Therapeutics Says Completed Patient Enrollment In Expanded Cohort Of Phase-1 Trial Testing MVT-5873

Dec 20 (Reuters) - Mabvax Therapeutics Holdings Inc :

* MABVAX THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND INITIAL PATIENT DOSING IN AN EXPANDED COHORT OF THE PHASE 1 TRIAL EVALUATING MVT-5873 IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY

* MABVAX THERAPEUTICS SAYS PLANS TO ANNOUNCE INTERIM SAFETY AND RECIST DATA Q1 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below